JP2015526443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526443A5 JP2015526443A5 JP2015527569A JP2015527569A JP2015526443A5 JP 2015526443 A5 JP2015526443 A5 JP 2015526443A5 JP 2015527569 A JP2015527569 A JP 2015527569A JP 2015527569 A JP2015527569 A JP 2015527569A JP 2015526443 A5 JP2015526443 A5 JP 2015526443A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- indazol
- benzoyl
- trifluoromethyl
- cyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 30
- -1 nitro, hydroxy Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 125000004694 alkoxyaminocarbonyl group Chemical group 0.000 claims 4
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 claims 2
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- VOVNWNVFKASLLY-UHFFFAOYSA-N 4-[1-(2-chloro-6-cyclopropylbenzoyl)-4-fluoroindazol-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C3CC3)N=2)=C1 VOVNWNVFKASLLY-UHFFFAOYSA-N 0.000 claims 1
- FTKZZUUQKBDHIQ-UHFFFAOYSA-N 4-[1-(2-chloro-6-methylbenzoyl)-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound CC1=CC=CC(Cl)=C1C(=O)N1C2=CC=CC(F)=C2C(C=2CCC(CC=2)C(O)=O)=N1 FTKZZUUQKBDHIQ-UHFFFAOYSA-N 0.000 claims 1
- WGVKQEUIMVZKMX-UHFFFAOYSA-N 4-[1-(2-chloro-6-methylbenzoyl)pyrazolo[4,3-b]pyridin-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound CC1=CC=CC(Cl)=C1C(=O)N1C2=CC=CN=C2C(C=2CCC(CC=2)C(O)=O)=N1 WGVKQEUIMVZKMX-UHFFFAOYSA-N 0.000 claims 1
- DTFLTTVMFQVAJF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-2-hydroxy-6-methylcyclohex-3-ene-1-carboxylic acid Chemical compound OC1C(C(O)=O)C(C)CC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 DTFLTTVMFQVAJF-UHFFFAOYSA-N 0.000 claims 1
- ULSWXLRBFXSKOO-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-2-hydroxycyclohex-3-ene-1-carboxylic acid Chemical compound C1CC(C(O)=O)C(O)C=C1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F ULSWXLRBFXSKOO-UHFFFAOYSA-N 0.000 claims 1
- CHMFHAIDDKZQQX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-4-methylcyclohexane-1-carboxylic acid Chemical compound N=1N(C(=O)C=2C(=CC=CC=2Cl)C(F)(F)F)C2=CC=CC(F)=C2C=1C1(C)CCC(C(O)=O)CC1 CHMFHAIDDKZQQX-UHFFFAOYSA-N 0.000 claims 1
- MZUYAAVZONNWFQ-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-5-methylcyclohex-3-ene-1-carboxylic acid Chemical compound CC1CC(C(O)=O)CC=C1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F MZUYAAVZONNWFQ-UHFFFAOYSA-N 0.000 claims 1
- DCEKJNKDTNIZBI-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]-6-hydroxycyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(O)=O)C(O)CC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 DCEKJNKDTNIZBI-UHFFFAOYSA-N 0.000 claims 1
- JAWOLYIAGCXUQG-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 JAWOLYIAGCXUQG-UHFFFAOYSA-N 0.000 claims 1
- RUZJPHPLVWPMFT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindazol-3-yl]cyclohex-3-ene-1-carboxylic acid;2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F.C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 RUZJPHPLVWPMFT-UHFFFAOYSA-N 0.000 claims 1
- PMCCAYCNHYFKOT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoroindol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=C(F)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=2)=C1 PMCCAYCNHYFKOT-UHFFFAOYSA-N 0.000 claims 1
- FHYRSAPXHJHYJO-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(2-hydroxyethylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)NCCO)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F FHYRSAPXHJHYJO-UHFFFAOYSA-N 0.000 claims 1
- DDQRUXMBXOJJAC-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(2-methylmorpholine-4-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1COC(C)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 DDQRUXMBXOJJAC-UHFFFAOYSA-N 0.000 claims 1
- VHAZQHNDEZQPAZ-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3,3-difluoroazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CC(F)(F)C2)=C1 VHAZQHNDEZQPAZ-UHFFFAOYSA-N 0.000 claims 1
- WYFJBTRWRCAZFU-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-fluoroazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CC(F)C2)=C1 WYFJBTRWRCAZFU-UHFFFAOYSA-N 0.000 claims 1
- QYKKDMJGDPIYER-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-hydroxyazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(O)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 QYKKDMJGDPIYER-UHFFFAOYSA-N 0.000 claims 1
- GMWBIQXNRGCABM-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-methoxyazetidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(OC)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 GMWBIQXNRGCABM-UHFFFAOYSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(3-methoxypyrrolidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-UHFFFAOYSA-N 0.000 claims 1
- LQXRTKDPFNHPJT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(4-methyl-3-oxopiperazine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(=O)N(C)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 LQXRTKDPFNHPJT-UHFFFAOYSA-N 0.000 claims 1
- GXTKLCIXWCBOHM-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(cyclopropylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)NC2CC2)=C1 GXTKLCIXWCBOHM-UHFFFAOYSA-N 0.000 claims 1
- YGFLUSDKSFGRBP-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(dimethylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F YGFLUSDKSFGRBP-UHFFFAOYSA-N 0.000 claims 1
- DSBPXNGBDIGBRF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(morpholine-4-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCOCC2)=C1 DSBPXNGBDIGBRF-UHFFFAOYSA-N 0.000 claims 1
- BOJKDICTPGZHJX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(piperidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCCCC2)=C1 BOJKDICTPGZHJX-UHFFFAOYSA-N 0.000 claims 1
- GRJJMWMGYUSJAR-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(propan-2-ylcarbamoyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)NC(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F GRJJMWMGYUSJAR-UHFFFAOYSA-N 0.000 claims 1
- VWMRDPIRRQMSDG-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(pyrrolidine-1-carbonyl)indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCCC2)=C1 VWMRDPIRRQMSDG-UHFFFAOYSA-N 0.000 claims 1
- WJSVXRQXYZLGEV-LDCVWXEPSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2r)-2-methylpyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@@H]1CCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WJSVXRQXYZLGEV-LDCVWXEPSA-N 0.000 claims 1
- DDQRUXMBXOJJAC-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2s)-2-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1CO[C@@H](C)CN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 DDQRUXMBXOJJAC-MYJWUSKBSA-N 0.000 claims 1
- WJSVXRQXYZLGEV-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(2s)-2-methylpyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@H]1CCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WJSVXRQXYZLGEV-MYJWUSKBSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-UHUGOGIASA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3r)-3-methoxypyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1[C@H](OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-UHUGOGIASA-N 0.000 claims 1
- WIWSXCVVUZWXLY-LDCVWXEPSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3r)-3-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@@H]1COCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WIWSXCVVUZWXLY-LDCVWXEPSA-N 0.000 claims 1
- YBBWSYMSKCZLKW-DAFXYXGESA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3s)-3-methoxypyrrolidine-1-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1[C@@H](OC)CCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 YBBWSYMSKCZLKW-DAFXYXGESA-N 0.000 claims 1
- WIWSXCVVUZWXLY-MYJWUSKBSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[(3s)-3-methylmorpholine-4-carbonyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C[C@H]1COCCN1C(=O)C1=CC=C(C(=NN2C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C=3CCC(CC=3)C(O)=O)C2=C1 WIWSXCVVUZWXLY-MYJWUSKBSA-N 0.000 claims 1
- DBVPUALOJKWZOW-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[1-hydroxy-3-(methylamino)propan-2-yl]oxycarbonylindazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)OC(CO)CNC)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DBVPUALOJKWZOW-UHFFFAOYSA-N 0.000 claims 1
- RURBILVXTPQNGT-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[2-hydroxyethyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(CCO)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F RURBILVXTPQNGT-UHFFFAOYSA-N 0.000 claims 1
- PPTPDSALMTVJCV-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[2-methoxyethyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)CCOC)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F PPTPDSALMTVJCV-UHFFFAOYSA-N 0.000 claims 1
- ASIUHIHZWLCGSX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[cyclopropyl(methyl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C=1C=C2C(C=3CCC(CC=3)C(O)=O)=NN(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C1CC1 ASIUHIHZWLCGSX-UHFFFAOYSA-N 0.000 claims 1
- MIVJIOPYWAUDFE-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]-6-[methyl(propan-2-yl)carbamoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C12=CC(C(=O)N(C)C(C)C)=CC=C2C(C=2CCC(CC=2)C(O)=O)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F MIVJIOPYWAUDFE-UHFFFAOYSA-N 0.000 claims 1
- WAZYMFVBHLCPOF-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 WAZYMFVBHLCPOF-UHFFFAOYSA-N 0.000 claims 1
- SRNRFQGJGFHEGN-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=NC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 SRNRFQGJGFHEGN-UHFFFAOYSA-N 0.000 claims 1
- RPNORSIVSACOLA-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]-2-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1CC(C(O)=O)C(C)C=C1C(C1=NC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F RPNORSIVSACOLA-UHFFFAOYSA-N 0.000 claims 1
- PSTVSHJRDIVFDL-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[4,3-b]pyridin-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=NC=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 PSTVSHJRDIVFDL-UHFFFAOYSA-N 0.000 claims 1
- OYBATLGLEZTBDT-UHFFFAOYSA-N 4-[4-chloro-1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]-1-methylcyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C)(C(O)=O)CCC(C=2C3=C(Cl)C=CC=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)=C1 OYBATLGLEZTBDT-UHFFFAOYSA-N 0.000 claims 1
- MZQZGAYLGDXZIQ-UHFFFAOYSA-N 4-[6-(azetidine-1-carbonyl)-1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]cyclohex-3-ene-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC(C=2C3=CC=C(C=C3N(C(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)N=2)C(=O)N2CCC2)=C1 MZQZGAYLGDXZIQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- IJFFCHQCDHHGDN-HAQNSBGRSA-N OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccc(F)c12 Chemical compound OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccc(F)c12 IJFFCHQCDHHGDN-HAQNSBGRSA-N 0.000 claims 1
- GNTUJCVVEKHONG-HAQNSBGRSA-N OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 Chemical compound OC(=O)[C@H]1CC[C@@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 GNTUJCVVEKHONG-HAQNSBGRSA-N 0.000 claims 1
- GNTUJCVVEKHONG-TXEJJXNPSA-N OC(=O)[C@H]1CC[C@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 Chemical compound OC(=O)[C@H]1CC[C@H](CC1)c1nn(C(=O)c2c(Cl)cccc2C(F)(F)F)c2cccnc12 GNTUJCVVEKHONG-TXEJJXNPSA-N 0.000 claims 1
- 102000016978 Orphan receptors Human genes 0.000 claims 1
- 108070000031 Orphan receptors Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000003702 retinoic acid receptors Human genes 0.000 claims 1
- 108090000064 retinoic acid receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- QSERINUGEFDOOJ-UHFFFAOYSA-N CC(N1N(C)C1)S=O Chemical compound CC(N1N(C)C1)S=O QSERINUGEFDOOJ-UHFFFAOYSA-N 0.000 description 1
- 0 CCSc1cccc(*)c1C(N(*=C(C1=*S)C2=CCC(*)CC2)C1=**=*)=O Chemical compound CCSc1cccc(*)c1C(N(*=C(C1=*S)C2=CCC(*)CC2)C1=**=*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/080133 | 2012-08-15 | ||
| PCT/CN2012/080133 WO2014026328A1 (en) | 2012-08-15 | 2012-08-15 | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| PCT/US2013/054902 WO2014028597A2 (en) | 2012-08-15 | 2013-08-14 | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526443A JP2015526443A (ja) | 2015-09-10 |
| JP2015526443A5 true JP2015526443A5 (cg-RX-API-DMAC7.html) | 2016-09-23 |
| JP6232429B2 JP6232429B2 (ja) | 2017-11-15 |
Family
ID=50101186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527569A Expired - Fee Related JP6232429B2 (ja) | 2012-08-15 | 2013-08-14 | ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用 |
Country Status (22)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| EP3428160A1 (en) * | 2013-08-02 | 2019-01-16 | Pfizer Inc | Heterobicycloaryl rorc2 inhibitors and methods of use thereof |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| EP3110429A4 (en) | 2014-02-27 | 2018-02-21 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| US9771374B2 (en) * | 2014-07-25 | 2017-09-26 | Innov17 Llc | Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| EP3172195A4 (en) * | 2014-07-25 | 2018-03-21 | Innov17 LLC | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof |
| US20170217956A1 (en) * | 2014-07-25 | 2017-08-03 | Innov17 Llc | Azaindole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| US9884847B2 (en) | 2014-07-25 | 2018-02-06 | Innov17 Llc | Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| MX371304B (es) | 2014-10-14 | 2020-01-24 | Vitae Pharmaceuticals Llc | Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma. |
| GB201419015D0 (en) | 2014-10-24 | 2014-12-10 | Orca Pharmaceuticals Ltd | Compounds |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CA2973185C (en) * | 2015-01-08 | 2021-02-16 | Advinus Therapeutics Limited | Bridgehead nitrogen bicyclic inhibitors/modulators of retinoic acid-related orphan receptor gamma (ror.gamma.) |
| US10322108B2 (en) | 2015-01-28 | 2019-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | N-benzoate group substituted benzopyrroline-2-one derivative and use thereof |
| CA2975157C (en) | 2015-01-30 | 2019-09-17 | Pfizer Inc. | Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof |
| EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| EP3268087A4 (en) | 2015-03-12 | 2018-08-29 | The Regents of the University of California | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| WO2016198908A1 (en) * | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| MA51556A (fr) * | 2015-06-09 | 2020-11-18 | Abbvie Inc | Modulateurs du récepteur nucléaire (ror) pour le traitement de maladies inflammatoires et auto-immunes |
| MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| AU2016355710B2 (en) | 2015-11-20 | 2021-03-25 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| JP2020111510A (ja) * | 2017-03-29 | 2020-07-27 | 科研製薬株式会社 | インダゾール誘導体及びそれを含有する医薬 |
| CN108727340B (zh) * | 2017-04-11 | 2020-12-29 | 广东东阳光药业有限公司 | 氟取代的吲唑类化合物及其用途 |
| WO2019007382A1 (zh) * | 2017-07-06 | 2019-01-10 | 江苏恒瑞医药股份有限公司 | 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| UA126583C2 (uk) | 2017-07-24 | 2022-11-02 | Вітае Фармасьютікалс, Ллс | ІНГІБІТОРИ ROR<font face="Symbol">g</font> |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
| WO2024149242A1 (zh) * | 2023-01-09 | 2024-07-18 | 成都百裕制药股份有限公司 | 一种杂环化合物及其在医药上的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| HUT75128A (en) * | 1994-03-30 | 1997-04-28 | Ciba Geigy Ag | Screening method using the rzr receptor family |
| US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| MX2007000791A (es) * | 2004-08-03 | 2007-03-23 | Wyeth Corp | Indazoles utiles en el tratamiento de enfermedades cardiovasculares. |
| AU2005286718A1 (en) * | 2004-09-21 | 2006-03-30 | Wyeth | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| US20090233955A1 (en) * | 2004-12-08 | 2009-09-17 | Frazee James S | 1H-Pyrrolo[2,3-B]Pyridnes |
| EP2181710A1 (en) | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands for modulation of orphan receptor-gamma (NR1F3) activity |
| EP2459184A1 (en) * | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| JP2014166961A (ja) * | 2011-06-20 | 2014-09-11 | Dainippon Sumitomo Pharma Co Ltd | 新規インダゾール誘導体 |
| WO2014026329A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026327A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
-
2012
- 2012-08-15 WO PCT/CN2012/080133 patent/WO2014026328A1/en not_active Ceased
-
2013
- 2013-08-14 ME MEP-2019-276A patent/ME03579B/me unknown
- 2013-08-14 BR BR112015003332A patent/BR112015003332A2/pt not_active IP Right Cessation
- 2013-08-14 PT PT138290994T patent/PT2884976T/pt unknown
- 2013-08-14 RU RU2015108898A patent/RU2015108898A/ru unknown
- 2013-08-14 DK DK13829099.4T patent/DK2884976T3/da active
- 2013-08-14 SI SI201331578T patent/SI2884976T1/sl unknown
- 2013-08-14 PL PL13829099T patent/PL2884976T3/pl unknown
- 2013-08-14 JP JP2015527569A patent/JP6232429B2/ja not_active Expired - Fee Related
- 2013-08-14 KR KR20157006342A patent/KR20150041800A/ko not_active Abandoned
- 2013-08-14 EP EP13829099.4A patent/EP2884976B1/en active Active
- 2013-08-14 WO PCT/US2013/054902 patent/WO2014028597A2/en not_active Ceased
- 2013-08-14 US US14/421,057 patent/US9487490B2/en active Active
- 2013-08-14 HU HUE13829099A patent/HUE045379T2/hu unknown
- 2013-08-14 AU AU2013302644A patent/AU2013302644A1/en not_active Abandoned
- 2013-08-14 ES ES13829099T patent/ES2749713T3/es active Active
- 2013-08-14 SM SM20190580T patent/SMT201900580T1/it unknown
- 2013-08-14 RS RSP20191289 patent/RS59364B1/sr unknown
- 2013-08-14 CN CN201380053426.7A patent/CN104822376A/zh active Pending
- 2013-08-14 HR HRP20191654 patent/HRP20191654T1/hr unknown
- 2013-08-14 LT LTEP13829099.4T patent/LT2884976T/lt unknown
- 2013-08-14 CA CA2881696A patent/CA2881696A1/en not_active Abandoned
-
2019
- 2019-10-04 CY CY20191101047T patent/CY1122272T1/el unknown